NCT00110578View on ClinicalTrials.gov

Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 1998

Study Completion Date

April 30, 2005

Conditions

HIV Infections

Interventions

PROCEDURE

Adoptive transfer of HIV-specific CD8+ T cells

DRUG

Aldesleukin

Trial Locations (2)

98109

Fred Hutchinson Cancer Research Center, Seattle

98122

University of Washington (UW), Seattle

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00110578 - Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults | Biotech Hunter | Biotech Hunter